Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Enterprise Value (2016 - 2026)

Iovance Biotherapeutics has reported Enterprise Value over the past 12 years, most recently at -$297.0 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$297.0 million for Q4 2025, up 8.28% from a year ago — trailing twelve months through Dec 2025 was -$297.0 million (up 8.28% YoY), and the annual figure for FY2025 was -$297.0 million, up 8.28%.
  • Enterprise Value for Q4 2025 was -$297.0 million at Iovance Biotherapeutics, up from -$300.8 million in the prior quarter.
  • Over the last five years, Enterprise Value for IOVA hit a ceiling of -$164.2 million in Q3 2024 and a floor of -$626.3 million in Q1 2023.
  • Median Enterprise Value over the past 3 years was -$301.0 million (2025), compared with a mean of -$320.8 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 54.57% in 2024 and later tumbled 83.23% in 2025.
  • Iovance Biotherapeutics' Enterprise Value stood at -$279.9 million in 2023, then dropped by 15.69% to -$323.8 million in 2024, then grew by 8.28% to -$297.0 million in 2025.
  • The last three reported values for Enterprise Value were -$297.0 million (Q4 2025), -$300.8 million (Q3 2025), and -$301.2 million (Q2 2025) per Business Quant data.